[The nasal mucosa permeability and toxicity of baicalin carrier systems liposomes, beta-cyclodextrin inclusion compound, and phospholipid complex].
To increase drug concentration in the head through intranasal administration, we have investigated the excised animal nasal mucosa permeability and nasal toxicity of the baicalin drug carrier systems, such as baicalin liposomes, beta-cyclodextrin inclusion compound, and phospholipid complex. A transport of baicalin drug carrier systems through nasal mucosa was simulated in diffusion chamber in vitro, and swine, caprine and rabbit nasal mucosa was used, the concentration of drug in the receptor was determined by HPLC. By taking the apparent permeability coefficients as evaluation standard, investigated the isolated animal nasal mucosa permeability of different baicalin drug systems was investigated for screening the best baicalin drug carrier system through nasal cavity administration. Toxicity of baicalin and its phospholipids complex on toad palate mucosal cilia movement and rats nasal mucosa long-term toxicity were studied in vivo. The apparent permeability coefficient of three kinds of baicalin drug carrier systems was better than that of baicalin (P < 0.05), and its lag-time was obviously shortened. At the same time, the apparent permeability coefficient of phospholipid complex was higher than those of other two drug carrier systems (P < 0.05). The results showed that the baicalin phospholipids complex nasal mucosa permeability was obviously superior to the other two drug systems. Baicalin phospholipids complex had no toxicity to ciliary movement, and had no irritation to rat nasal mucosa. The results show that baicalin phospholipid complex was the best baicalin drug carrier system, it could significantly enhance the permeability of baicalin across nasal mucosa, had no toxicity to nasal mucosa, and could be used for intranasal administration.
Wu
Pin-jiang
PJ
Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Xu
Run-chun
RC
Su
Zhe-tong
ZT
Wei
Ping
P
Lin
Yan-jun
YJ
Yang
Ming
M
Zheng
Qin
Q
D000281:Administration, Intranasal; D000818:Animals; D002023:Bufo bufo; D004337:Drug Carriers / Q000493:pharmacokinetics* / Q000633:toxicity; D016503:Drug Delivery Systems; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D006041:Goats; D008081:Liposomes / Q000493:pharmacokinetics / Q000633:toxicity; D008297:Male; D009297:Nasal Mucosa / Q000187:drug effects / Q000378:metabolism*; D010159:Palate / Q000187:drug effects; D010539:Permeability; D010743:Phospholipids / Q000493:pharmacokinetics* / Q000633:toxicity; D011817:Rabbits; D011897:Random Allocation; D051381:Rats; D013552:Swine; D047392:beta-Cyclodextrins / Q000493:pharmacokinetics / Q000633:toxicity
D004337:Drug Carriers; D005419:Flavonoids; D008081:Liposomes; D010743:Phospholipids; D047392:beta-Cyclodextrins; C038044:baicalin; C031215:betadex